Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

r requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave or Empatic to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave or Empatic, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... -- An entire month is dedicated to one of the ... (CMT) – a debilitating neuromuscular disease affecting the arms, ... and foot and hand deformities. CMT affects 1 in ... a progressive disease, and over time patients lose the ... as leg braces, wheelchairs and scooters to get around. ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... preclinical studies characterizing the analgesic profiles of a ... opioid receptor agonist molecules. The preclinical research candidates ... chemistry platform. The analgesic properties of ... medical literature. 1,2 Kappa opioid receptors are ...
(Date:9/19/2014)... 2014 BioTech News Coverage: Progress ... results of studies and trials.  Companies in focus are: ... LLY ), Gilead Sciences Inc. (NASDAQ: ... ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... therapeutics for the treatment of cancer, announced that the ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
... High transduction efficiency and predictable copy number , ... , Katherine Felts John C. Bauer Peter ... pFB-Neo can be used with any,Moloney Murine Leukemia Virus ... be used to infect a wide range of cell ...
... expression of heterologous proteins , Carsten-Peter Carstens ... ,Stratagene , Codon bias is a significant obstacle ... hosts. In GC-rich genomes, such as mammals,rare arginine ... (CCC) most frequently,affect bacterial gene expression. For such ...
... mixture, TaqPlus Precision PCR system, developed for,highfidelity PCR ... Frances Bai * Daniel McMullan,* Barbara McGowan * Holly ... the addition of the TaqPlus Precision PCR system,* to ... PCR system,consists of a novel mixture of Taq2000 and ...
Cached Biology Technology:High-Titer ,Retroviral Vectors for Gene Delivery 2High-Titer ,Retroviral Vectors for Gene Delivery 3High-Titer ,Retroviral Vectors for Gene Delivery 4High-Titer ,Retroviral Vectors for Gene Delivery 5High-Titer ,Retroviral Vectors for Gene Delivery 6High-Titer ,Retroviral Vectors for Gene Delivery 7High-Titer ,Retroviral Vectors for Gene Delivery 8New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 2New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 3New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 4High-Fidelity PCR with a Novel Polymerase Mixture 2High-Fidelity PCR with a Novel Polymerase Mixture 3High-Fidelity PCR with a Novel Polymerase Mixture 4High-Fidelity PCR with a Novel Polymerase Mixture 5High-Fidelity PCR with a Novel Polymerase Mixture 6High-Fidelity PCR with a Novel Polymerase Mixture 7High-Fidelity PCR with a Novel Polymerase Mixture 8High-Fidelity PCR with a Novel Polymerase Mixture 9High-Fidelity PCR with a Novel Polymerase Mixture 10High-Fidelity PCR with a Novel Polymerase Mixture 11
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
(Date:9/18/2014)... turned its newborn screening program into a model other states ... the first-ever Newborn Screening Quality Award from the March of ... M.P.H., Arizona,s Department of Health Services director, with the award ... policy of full transparency for the length of time it ... lab for analysis, and set a target of having 95 ...
(Date:9/18/2014)... Eight researchers from several disciplines will be celebrated tonight ... their roles in improving the health of premature infants ... supercomputing revolutions. The researchers, whose work was supported by ... and the former Atomic Energy Commission, will be honored ... Washington, DC. A bipartisan group of Members of Congress ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... (BRONX, NY) Researchers from the Albert Einstein ... developed an onsite method to quickly diagnose tuberculosis (TB) ... undetected with treatable TB strains. This study will ... online journal from the Public Library of Science. ...
... 19, 2009Recognition of the benefits of cooling strategies to ... has led to a wealth of cutting edge research, ... hypothermia issue of Journal of Neurotrauma , a ... www.liebertpub.com ). The issue will be available free online ...
... is 2065. Nearly two-thirds of Earth,s ozone is gone -- ... hole over Antarctica, first discovered in the 1980s, is a ... ultraviolet (UV) radiation falling on mid-latitude cities like Washington, D.C., ... DNA-mutating UV radiation is up 650 percent, with likely harmful ...
Cached Biology News:Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time 2Therapeutic hypothermia is promising strategy to minimize tissue damage 2New simulation shows consequences of a world without Earth's natural sunscreen 2New simulation shows consequences of a world without Earth's natural sunscreen 3New simulation shows consequences of a world without Earth's natural sunscreen 4
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Request Info...
... Storage Racks for Standard 3" Boxes. ... all makes and models of upright ... high quality stainless steel and can ... steel or plastic boxes. Custom ...
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: